

# Puma Biotechnology

## Earnings Call

### Commercial Update



**August 6, 2026**

**nerlynx<sup>®</sup>**  
(neratinib) tablets




## Forward-Looking Safe-Harbor Statement

*This presentation contains forward-looking statements, including statements regarding commercialization of NERLYNX® and the potential indications and development of our drug candidates. All forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on our current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, any adverse impact on our business or the global economy and financial markets and the risk factors disclosed in our periodic and current reports filed with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent filings. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We assume no obligation to update these forward-looking statements except as required by law.*




# Puma's Pharmacy and Distributor Network



# \$53.6 Million Net NERLYNX Revenue in Q2'26


*~9% increase in Q2'26 compared to Q2'25*



**Inventory Change (\$)**

| Q2'25      | Q2'26    |
|------------|----------|
| -\$1.3 mil | -\$1 mil |

*~28% increase in Q2'26 compared to Q1'26*




**Inventory Change (\$)**


| Q1'26      | Q2'26    |
|------------|----------|
| -\$7.9 mil | -\$1 mil |

# 2,929 Ex-Factory Bottles Were Sold in Q2'26

*~12% increase in Q2'26 compared to Q2'25*




*~26% increase in Q2'26 compared to Q1'26*




# 2,986 bottles of U.S. Commercial Demand in Q2'26

*~11% increase in Q2'26 compared to Q2'25*



*~8% increase in Q2'26 compared to Q1'26*



# Rest of World Partnerships – Timelines

| Region                                                                                    | Partner                                                                             | Regulatory Approvals                                                                                                                                                                                                                                                                                                                                            | Commercial Launches                                                                                                                                                                                                                                                                                                                                                                       |
|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Australia / SE Asia                                                                       |    | <ul style="list-style-type: none"> <li>• 2019 – Ext. Adj. in Australia, Singapore</li> <li>• 2020 – Ext. Adj. in Brunei, Malaysia, New Zealand</li> <li>• 2022 – Ext. Adj. in the Philippines; mBC in Singapore</li> <li>• 2023 – mBC in Malaysia</li> <li>• 2024 – Ext. Adj. and mBC in Thailand</li> </ul>                                                    | <ul style="list-style-type: none"> <li>• 2020 – Singapore</li> <li>• 2021 – Malaysia, Brunei, New Zealand</li> <li>• Q1 2026 - Thailand</li> </ul>                                                                                                                                                                                                                                        |
| Israel                                                                                    |    | <ul style="list-style-type: none"> <li>• 2020 – Approved in Ext. Adj. and mBC</li> </ul>                                                                                                                                                                                                                                                                        | <ul style="list-style-type: none"> <li>• 2020 – Launched</li> </ul>                                                                                                                                                                                                                                                                                                                       |
| Canada                                                                                    |    | <ul style="list-style-type: none"> <li>• 2019 – Ext. Adj. approved</li> <li>• 2021 – mBC approved</li> </ul>                                                                                                                                                                                                                                                    | <ul style="list-style-type: none"> <li>• 2020 – Launched</li> </ul>                                                                                                                                                                                                                                                                                                                       |
| Latin America                                                                             |    | <ul style="list-style-type: none"> <li>• 2019 – Ext Adj in Argentina</li> <li>• 2020 – Ext. Adj in Chile, Ecuador; mBC in Argentina</li> <li>• 2021 – Ext Adj. and mBC in Peru; mBC in Chile; Ext. Adj. in Brazil</li> <li>• 2022 – Ext. Adj. in Mexico; mBC in Ecuador</li> <li>• 2023 – mBC in Colombia and Mexico</li> <li>• 2024 – mBC in Brazil</li> </ul> | <ul style="list-style-type: none"> <li>• 2020 – Argentina</li> <li>• 2021 – Chile and Peru</li> <li>• 2022 – Brazil</li> <li>• 2023 – Mexico and Colombia</li> </ul>                                                                                                                                                                                                                      |
| Europe<br>Greater China<br>Middle East<br>North and West Africa<br>South Africa<br>Turkey |   | <ul style="list-style-type: none"> <li>• 2019 – Ext. Adj. EMA and Hong Kong</li> <li>• 2020 – Ext. Adj. in China, Taiwan</li> <li>• 2021 – mBC in Taiwan</li> <li>• 2023 – Ext. Adj. in Morocco, South Africa, and UAE</li> <li>• 2024 – Ext. Adj. in Syria, Saudi Arabia, Algeria, Turkey</li> <li>• 2025 – Ext. Adj. in Lebanon</li> </ul>                    | <ul style="list-style-type: none"> <li>• 2019 – Germany, UK, Austria</li> <li>• 2020 – Sweden, Finland, Scotland, Switzerland, Denmark, HK</li> <li>• 2021 – China, Taiwan, Greece, Czech Republic, Luxembourg</li> <li>• 2022 – Ireland, Spain</li> <li>• 2023 – Slovakia</li> <li>• 2024 – Morocco, South Africa, UAE, Turkey, Saudi Arabia</li> <li>• 2025 – Libya, Algeria</li> </ul> |
| South Korea                                                                               |  | <ul style="list-style-type: none"> <li>• 2021 – Ext. Adj. in S. Korea</li> </ul>                                                                                                                                                                                                                                                                                | <ul style="list-style-type: none"> <li>• 2022 – Launched</li> </ul>                                                                                                                                                                                                                                                                                                                       |
| Russia/CIS                                                                                |  | <ul style="list-style-type: none"> <li>• Distribution agreement executed</li> </ul>                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                           |

# Puma Biotechnology

## Earnings Call

### Commercial Update



**August 6, 2026**

**nerlynx<sup>®</sup>**  
(neratinib) tablets

